UK's leading clinical research organisation

Since 2001, Richmond Pharmacology has conducted over 500 Early Phase Studies, delivering exceptional customer service, and exceeding the expectations of our sponsors. We have significant experience in running a range of patient trials, adding value to the studies by incorporating detailed analysis of the cardiovascular effects of drugs.
‍
We are industry leaders in Adaptive Phase I and II studies, Thorough-QT, Japanese Bridging Studies and Patient Recruitment. Our services span consultancy and concept development through to final reporting.
‍
As a sponsor, you will receive a personal and truly strategic experience and our knowledgeable staff will ensure your trial delivers meaningful results.

Our business ethos is unique:
Our business is sustainable, adaptive to change and is led by the same specialists who founded Richmond Pharmacology nineteen years ago. Our founders are involved in each clinical research trial, so you are assured of a personal service throughout.
‍
We are committed to advancing science and improving patient safety. Our revenues are reinvested in the business and the newly developed, not-for-profit research organisation – Richmond Research Institute. The Institute was born from our partnership with St George’s University London and a mutual desire to expand academic research in key fields of cardiology, hepatology, clinical trial methodology and racial and sex differences in human physiology.